Nipro Pharma Corporation
Nipro Pharma Corporation, a leading player in the pharmaceutical industry, is headquartered in Japan and operates extensively across Asia, Europe, and the Americas. Founded in 1954, the company has established itself as a key provider of high-quality medical products, particularly in the fields of dialysis, infusion therapy, and injectable pharmaceuticals. Nipro's commitment to innovation is evident in its diverse range of core products, which include advanced medical devices and pharmaceutical formulations designed to enhance patient care. The company is recognised for its rigorous quality standards and has achieved significant milestones, including numerous certifications and awards that underscore its market position. With a focus on research and development, Nipro Pharma continues to drive advancements in healthcare, making it a trusted name in the global pharmaceutical landscape.
DitchCarbon Score
How does Nipro Pharma Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nipro Pharma Corporation's score of 27 is lower than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Nipro Pharma Corporation's reported carbon emissions
Nipro Pharma Corporation, headquartered in Japan (JP), currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Nipro Corporation, which may influence its climate commitments and emissions reporting. As of now, Nipro Pharma Corporation has not established any documented reduction targets or commitments under the Science Based Targets initiative (SBTi) or other climate pledges. The absence of specific emissions data and reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given the context of the pharmaceutical industry, which is increasingly focusing on sustainability and carbon footprint reduction, Nipro Pharma Corporation may benefit from aligning its efforts with industry standards and best practices. This could include setting measurable targets for emissions reductions and participating in initiatives like the Carbon Disclosure Project (CDP), from which it inherits data through its parent company, Nipro Corporation. In summary, while Nipro Pharma Corporation currently lacks specific emissions data and reduction commitments, its affiliation with Nipro Corporation may provide a pathway for future climate action and reporting.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Nipro Pharma Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
